文献速递淋巴瘤

慢性型与冒烟型成人T细胞白血病-淋巴瘤的预后指数

Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.
PubMed 文献 · Blood · 2017-05-17

本研究基于全国性回顾性调查的248例慢性型与冒烟型成人T细胞白血病-淋巴瘤(ATL)患者,开发并验证了新型预后指数iATL-PI。多因素分析仅log10(可溶性白细胞介素-2受体[sIL-2R])为独立预后因素,iATL-PI=1.51×log10(sIL-2R[U/mL])。验证样本中高、中、低危组中位生存期分别为1.6年、5.5年、未达到(P<.0001)。简化版以sIL-2R 1000和6000 U/mL三分位分组,中位生存期分别为1.6年、未达到、5.5年(P<.0001)。

要点

  • iATL-PI仅基于log10(sIL-2R)计算,公式为1.51×log10(sIL-2R[U/mL])。
  • 验证样本中高、中、低危组中位生存期分别为1.6年、5.5年、未达到(P<.0001)。
  • 简化版以sIL-2R 6000 U/mL以上为高危、1000 U/mL及以下为低危、其余为中危。

核心结论

  • iATL-PI有潜力作为风险适应治疗策略的新工具。

研究设计与样本

  • 全国性回顾性调查,248例完全符合条件的ATL患者纳入分析,用于开发慢性型与冒烟型ATL的预后指数。

主要发现

  • 训练样本单因素分析中,性别、体能状态、log10(sIL-2R)、中性粒细胞计数和淋巴结肿大P<.05。
  • 训练样本多因素分析仅log10(sIL-2R)被确定为独立预后因素。
  • 验证样本中高、中、低危组中位生存期分别为1.6年、5.5年、未达到(P<.0001)。
  • 简化版高危(sIL-2R>6000 U/mL)、中危(sIL-2R>1000且≤6000 U/mL)、低危(sIL-2R≤1000 U/mL)组中位生存期分别为1.6年、5.5年、未达到(P<.0001)。

关键数值与推荐

  • iATL-PI=1.51×log10(sIL-2R[U/mL]),按四分位点分为3组。
  • 简化版以sIL-2R 1000和6000 U/mL三分位分组:>6000 U/mL为高危,≤1000 U/mL为低危,其余为中危。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adult T-cell leukemia-lymphoma (ATL) has been divided into 4 clinical subtypes: acute, lymphoma, chronic, and smoldering. The aim of this study is to develop a novel prognostic index (PI) for chronic and smoldering ATL. We conducted a nationwide retrospective survey on ATL patients, and 248 fully eligible individuals were used in this analysis. In the univariate analysis, sex, performance status, log10 (soluble interleukin-2 receptor [sIL-2R]), neutrophils count, and lymphadenopathy showed values of P < .05 in training samples. A multivariate analysis was performed on these factors, and only log10 (sIL-2R) was identified as an independent prognostic factor in training samples. Using a regression coefficient of this variable, a prognostic model was formulated to identify different levels of risk: indolent ATL-PI (iATL-PI) = 1.51 × log10 (sIL-2R [U/mL]). The values calculated by iATL-PI were divided into 3 groups using a quartile point. In the validation sample, median survival times (MSTs) were 1.6 years, 5.5 years, and not reached for patients in the high-, intermediate-, and low-risk groups, respectively (P < .0001). To make the scoring system clinically practicable, we simplified iATL-PI according to trichotomizing sIL-2R at 1000 and 6000 U/mL, using a quartile point. Patients with more than 6000 U/mL sIL-2R were categorized into the high-risk group, less than and equal to 1000 U/mL into the low-risk group, and the others into the intermediate-risk group, and MSTs were 1.6 years, not reached, and 5.5 years, respectively (P < .0001). iATL-PI has potential as a novel tool for a risk-adapted therapeutic approach.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Katsuya H, Shimokawa M, Ishitsuka K, et al. Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood. 2017. PMID: 28515095. doi:10.1182/blood-2017-01-757542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。